Novo Signs Delivery Deal With Nanexa Worth Up to $1.3 Billion
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB for rights to its drug delivery technology for obesity and diabetes treatments.
By Charles Daly and Sanne Wass · Bloomberg
Novo Nordisk A/S signed a deal worth as much as €1.165 billion ($1.3 billion) with Sweden’s Nanexa AB for rights to its drug delivery technology for obesity and diabetes treatments.